Guardant Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Guardant Health, Inc. on June 10, 2022. The report details the completion of a significant corporate transaction involving the company's joint venture in the Asia, Middle East, and Africa (AMEA) region.
Key Financial Metrics
The filing discloses a specific transaction value but does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics for the reporting period.
- Transaction Value: $177,785,000 aggregate purchase price.
- Valuation Basis: Determined based on an independent third-party valuation.
Material Changes
On June 10, 2022, Guardant Health completed the purchase of all shares held by SoftBank (SVF Excalibur (Cayman) Limited and affiliates) in Guardant Health AMEA, Inc. (the "AMEA Joint Venture"). This transaction was executed pursuant to a call right exercised by the Company in November 2021 under the Joint Venture Agreement dated May 9, 2017. Concurrent with the closing, the JV Agreement was terminated, and SoftBank-nominated board members resigned.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, forward-looking outlooks, or specific risk factors beyond the disclosure of the completed transaction. The event is categorized as the termination of a material definitive agreement and an "Other Event."
Key Facts for Investor Verification
- Verify the impact of the $177.8 million cash outflow on the company's liquidity and cash position in subsequent quarterly reports.
- Confirm the full consolidation of the AMEA Joint Venture's financial results into Guardant Health's future reporting.
- Review the press release filed as Exhibit 99.1 for additional strategic context regarding the AMEA region.
- Note that this filing does not contain standard operating metrics (revenue, margins) for the period.